Anastasis

I mean, it sincerely did not start out that way, but the responses of others here can be classified as nothing other than trolling. No mirrors in the CR.

Now y'all believe in science again. What a world.

I mean, you know.

All I said initially was that "There is not a single person I talk to in real life that thinks the current climate is winning. YMMV." This triggers some posters here. But I cannot be held responsible for that. Some of them have a long history of being triggered when confronted with common sense observations.

There is certainly something to this wrt to the multiplier effect. But it's not limited to those with multipliers.

I am with you man.

It's important to remember how totally disconnected from reality the CR has been for years.

It's kinda amazing the fantasy land that some of you create around posters. YMMV.

It's up to debate who is in fact stupid here. I appreciate that it is anathema to this crowd to roll out there that daily cost of living is insane right now compared to recent past, cause it will be interpreted in political terms and orange man is bad. It's crazy to point out that people are feeling a pinch at basically every level of "fixed expense". It's crazy to suggest that data on 401k millionaires is fundamentally meaningless to people in the here and now, and that any of that influences their sentiment regarding all the winning right now. It must be a failure of those people across the political spectrum just failing to understand.

You should go into political consultancy. Nobody that I talked to today was stupid by any measure, objective or subjective. Again, politics breaking brains.

None of these conversations were in a bar, and data are obviously always relevant. How those data points translate, or do not, to the sentiments and lived experiences of real people running the treadmill matter. Not surprised by the push back, but quite comfortable with my comments.

I think that there is a disconnect between the data and the sentiment. Just my opinion. I don't think that it translates to the ballot box, so I still think that Kamala is going to run away with this. But again, I am not having any conversations with people that are doing backflips about the economic climate they feel day to day. Maybe I am just no running in the right circles.

Maybe. Grab a seat at any table in any bar in this country and strike up a conversation. Report back where that lands.

Maybe touch grass?

It was a interesting stream of conversations across professional and personal interactions, but conversations literally just today. Chinese, Indian, White, Mexican, South American. A mix of professional W2 stiffs like me and a buddy from HS that owns his own landscape business. The latter was the most vocal in terms of couching it in the political terms directly relevant. But there was widespread consensus that the trajectory over the last few years ain't sustainable. CR is full of very vocal clowns many of which seem to have no connection to reality.

Politics breaks brains. There is not a single person I talk to in real life that thinks the current climate is winning. YMMV.

The beat goes on...

Their floor is certainly cleaner with fewer fluid stains than my garage.

Unsurprising for Abbvie. https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html How a Drug Company Made $114 Billion by Gaming the U.S. Patent System AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end. By Rebecca Robbins Jan. 28, 2023 In 2016, a blockbuster drug called Humira was poised to become a lot less valuable. The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug, and more copycats were close behind. The onset of competition seemed likely to push down the medication’s $50,000-a-year list price. Instead, the opposite happened. Through its savvy but legal exploitation of the U.S. patent system, Humira’s manufacturer, AbbVie, blocked competitors from entering the market. For the next six years, the drug’s price kept rising. Today, Humira is the most lucrative franchise in pharmaceutical history.

We genocide democracy when democratic outcomes are not aligned with our foreign policy objectives.

A day's supply. The vial is single use and expires after 24h. Max dose is two and a half vials per day. So anywhere from let's call it $40-80k per year. Plus the hardware.

My understanding after reading a bit is that active ingredients are highly soluble prodrug formulations (after absorption the body metabolizes the prodrug foslevodopa into the drug levodopa by chopping off the "fos"). So not exactly the old treatment, but with just a very minor molecular tweak to make the subcutaneous infusion viable. Not sure how any of that shakes out wrt the patents. It's a $62k/year drug in Canada. Not sure what pricing concessions NHS got, but it would probably be in the six figures range in the US.

Yeah, that's a pretty cool before/after shot. Not really a new drug though, a new delivery mechanism (infusion) that smooths out the on/off effects. The active ingredients are basically the same as what PD has been treated with for decades (levodopa/carbidopa). Video is probably a bit misleading in terms of differentiating this from existing treatments. You can see the same short-term effects with administration of simple oral levo/carbidopa. The differentiator appears to the be the increase in on time and the reduction in off time over extended periods with the infusion. Balanced by greater frequency of side effects and side effect related treatment discontinuation. I think that the FDA eventually approves it as the hang up appears to be manufacturing. Would be more interesting to compare it head up to extended release orals and/or the GI administered form. The real advance here appears to be that compared to the GI infusion this doesn't require surgical placement. Findings Between Oct 19, 2020, and Sept 29, 2021, of 270 participants screened and 174 enrolled, 141 were randomly assigned and received continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo capsules (n=74) or oral encapsulated immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution (n=67). Compared with levodopa-carbidopa, foslevodopa-foscarbidopa showed a significantly greater increase in on time without troublesome dyskinesia (model-based mean [SE] 2·72 [0·52] vs 0·97 [0·50] h; difference 1·75 h, 95% CI 0·46 to 3·05; p=0·0083) and a significantly greater reduction in off time (−2·75 [0·50] vs −0·96 [0·49] h; difference −1·79 h, −3·03 to −0·54; p=0·0054). Hierarchical testing ended after the first secondary endpoint. Adverse events were reported in 63 (85%) of 74 patients in the foslevodopa-foscarbidopa group versus 42 (63%) of 67 in the levodopa-carbidopa group, and incidences of serious adverse events were similar between the groups (six [8%] of 74 vs four [6%] of 67, respectively). The most frequent adverse events in the foslevodopa-foscarbidopa group were infusion site adverse events (erythema 20 [27%]), pain 19 [26%]), cellulitis (14 [19%]), and oedema (nine [12%]), most of which were non-serious and mild–moderate in severity. The only system organ class that had more than one serious adverse event in the foslevodopa-foscarbidopa group was infections and infestations (catheter site cellulitis [one [1%]] and infusion site cellulitis [one [1%]). Adverse events led to premature discontinuation of study drug in 16 (22%) of 74 participants in the foslevodopa-foscarbidopa group versus one (1%) of 67 participants in the oral levodopa-carbidopa group.

Any idea how many man-hours?

eform timeline update form 4, trust, via silencershop purchased 02/2024 certified 03/06/2024 approved 08/27/2024 About half as long as my first one, IIRC.